CoChat

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer

Open access
Yu, Hui, Batenchuk, Cory, Badzio, Andrzej, Boyle, Theresa A., Czapiewski, Piotr, Chan, Daniel C., Lu, Xian, Gao, Dexiang, Ellison, Kim, Kowalewski, Ashley A., Rivard, Christopher J., Dziadziuszko, Rafal, Zhou, Caicun, Hussein, Maen, Richards, Donald, Wilks, Sharon, Monte, Marc, Edenfield, William, Goldschmidt, Jerome, Page, Ray, Ulrich, Brian, Waterhouse, David, Close, Sandra, Jassem, Jacek, Kulig, Kimary, Hirsch, Fred R. · 2017 · Journal of Thoracic Oncology
Cited by 135

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Introduction: Therapeutic antibodies to immune checkpoints show promising results. Programmed death‐ligand 1 (PD‐L1), an immune checkpoint ligand, blocks the cancer immunity cycle by binding the PD‐L1 receptor (programmed death 1). We investigated PD‐L1 protein expression and messenger RNA (mRNA) levels in SCLC. Methods: PD‐L1 protein expression and mRNA levels were determined by immunohistochemistry (IHC) with SP142 and Dako 28‐8 PD‐L1 antibodies and in situ hybridization in primary tumor tissue microarrays in both tumor cells and tumor‐infiltrating immune cells (TIICs) obtained from a limited‐disease SCLC cohort of 98 patients. An additional cohort of 96 tumor specimens from patients with extensive‐disease SCLC was assessed for PD‐L1 protein expression in tumor cells with Dako 28‐8 antibody only. Results: The overall prevalence of PD‐L1 protein expression in tumor cells was 16.5%. In the limited‐disease cohort, the prevalences of PD‐L1 protein expression in tumor cells with SP142 and Dako 28‐8 were 14.7% and 19.4% (tumor proportion score cutoff ≥1%) and PD‐L1 mRNA ISH expression was positive in 15.5% of tumor samples. Increased PD‐L1 protein/mRNA expression was associated with the presence of more TIICs (p < 0.05). The extensive‐disease cohort demonstrated a 14.9% positivity of PD‐L1 protein expression in tumor cells with Dako 28‐8 antibody. Conclusions: A subset of SCLCs is characterized by positive PD‐L1 and/or mRNA expression in tumor cells. Higher PD‐L1 and mRNA expression correlate with more infiltration of TIICs. The prevalence of PD‐L1 in SCLC is lower than that published for NSCLC. The predictive role of PD‐L1 expression in SCLC treatment remains to be established.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2016.09.002

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 135

Metadata

Authors
Yu, H., Batenchuk, C., Badzio, A., Boyle, T. A., Czapiewski, P., Chan, D. C., Lu, X., Gao, D., Ellison, K., Kowalewski, A. A., Rivard, C. J., Dziadziuszko, R., Zhou, C., Hussein, M., Richards, D., Wilks, S., Monte, M., Edenfield, W., Goldschmidt, J., Page, R., Ulrich, B., Waterhouse, D., Close, S., Jassem, J., Kulig, K., & Hirsch, F. R.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2017-01
Volume
12
Issue
1
Pages
110-120
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2519113433
Cited by
135
References
12
FWCI
7.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.